Basic Information
| LncRNA/CircRNA Name | LINC01061 |
| Synonyms | NA |
| Region | GRCh38_1:29554-31109 |
| Ensemble | |
| Refseq | NR_037596 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | papillary thyroid cancer |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, luciferase reporter assay |
| Sample | papillary thyroid cancer tissues, cell lines (TPC-1, IHH4) |
| Expression Pattern | up-regulated |
| Function Description | The genomic copy number of LINC01061 is amplified, which leads to its elevated expression level in PTC tissues. Functional study indicated that LINC01061 silence significantly inhibited the proliferation, cell-cycle and invasion of PTC cells in vitro and tumor growth in vivo. Mechanistically, we showed that LINC01061 interacted with miR-4316 to promote E2F6 expression. Moreover, Kaplan-Meier curve analysis showed that LINC01061 high expression correlates with lower survival rate, indicating LINC01061 might be a potential prognostic biomarker. We have observed LINC01061 correlates with metastasis in PTC patients. |
| Pubmed ID | 30029886 |
| Year | 2018 |
| Title | DNA Copy Number Gain-Mediated lncRNA LINC01061 Upregulation Predicts Poor Prognosis and Promotes Papillary Thyroid Cancer Progression. |
External Links
| Links for LINC01061 | GenBank HGNC NONCODE |
| Links for papillary thyroid cancer | OMIM COSMIC |